medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 3

<< Back Next >>

Ann Hepatol 2016; 15 (3)

Is intestinal oxidative stress involved in patients with compensated liver cirrhosis?

Pijls KE, Jonkers DMAE, Elizalde M, Drittij-Reijnders Marie-Jose; Haenen GR, Bast A, Masclee AAM, Koek GH

Language: English
References: 36
Page: 402-409
PDF size: 170.96 Kb.


ABSTRACT

Background. Liver cirrhosis is associated with intestinal epithelial barrier dysfunction, which may be affected by oxidative stress. Studies in cirrhotic rats provided evidence for intestinal oxidative stress, but studies in cirrhotic patients are scarce. We have shown intestinal barrier dysfunction in patients with compensated cirrhosis. Aim. The present study aimed to investigate whether oxidative stress occurs in the intestinal mucosa of compensated cirrhotic patients and may contribute to barrier dysfunction. Material and methods. Oxidative stress was studied in duodenal and sigmoid biopsies from 15 cirrhotic patients and 22 controls by analyzing transcription of genes involved in glutathione and uric acid metabolism using quantitative real-time polymerase chain reaction. Protein levels of glutathione and glutathione disulphide were measured and the glutathione/glutathione disulphide ratio was calculated as marker of oxidative stress. In addition, intestinal myeloperoxidase and fecal calprotectin were determined. Results. Gene transcription of glutathione synthetase and glutathione reductase were significantly different in duodenal and sigmoid biopsies of cirrhotic patients vs. controls, but no alterations were found for other genes nor for glutathione, glutathione disulphide, glutathione/glutathione disulphide ratio and intestinal myeloperoxidase and fecal calprotectin concentrations. Conclusion. This study did not find indications for oxidative stress and low-grade inflammation in the small and large intestine of stable compensated cirrhotic patients. Although these preliminary findings need further validation, we found intestinal oxidative stress not to be a major mechanism contributing to epithelial barrier dysfunction in patients with compensated cirrhosis.


REFERENCES

  1. Misra V, Misra SP, Dwivedi M, Gupta SC. Histomorphometric study of portal hypertensive enteropathy. Am J Clin Pathol 1997; 108: 652-7.

  2. Such J, Guardiola JV, de Juan J, Casellas JA, Pascual S, Aparicio JR, Sola-Vera J, et al. Ultrastructural characteristics of distal duodenum mucosa in patients with cirrhosis. Eur J Gastroenterol Hepatol 2002; 14: 371-6.

  3. Chesta J, Defilippi C. Abnormalities in proximal small bowel motility in patients with cirrhosis. Hepatology 1993; 17: 828-32.

  4. Chen Y, Yang F, Lu H, Wang B, Lei D, Wang Y, Zhu B, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011; 54: 562-72.

  5. Campillo B, Pernet P, Bories PN, Richardet JP, Devanlay M, Aussel C. Intestinal permeability in liver cirrhosis: relationship with severe septic complications. Eur J Gastroenterol Hepatol 1999; 11: 755-9.

  6. Zuckerman MJ, Menzies IS, Ho H, Gregory GG, Casner NA, Crane RS, Hernandez JA. Assessment of Intestinal Permeability and Absorption in Cirrhotic Patients with Ascites Using Combined Sugar Probes. Dig Dis Sci 2004; 49: 621-6.

  7. Norman K, Pirlich M, Schulzke JD, Smoliner C, Lochs H, Valentini L, Buhner S. Increased intestinal permeability in malnourished patients with liver cirrhosis. Eur J Clin Nutr 2012; 66: 1116-9.

  8. Bellot P, Frances R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 2013; 33: 31-9.

  9. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422-33.

  10. Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, Karatza E, Triantos C, Vagianos CE, Spiliopoulou, et al. Altered intestinal tight junctions’ expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Invest 2012; 42: 439-46.

  11. Du Plessis J, Vanheel H, Janssen CE, Roos L, Slavik T, Stivaktas PI, Nieuwoudt M, et al. Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol 2013; 58: 1125-32.

  12. Rao RK, Basuroy S, Rao VU, KarnakyJr KJ, Gupta A. Tyrosine phosphorylation and dissociation of occludin-ZO-1 and Ecadherin-beta-catenin complexes from the cytoskeleton by oxidative stress. Biochem J 2002; 368: 471-81.

  13. Ramachandran A, Prabhu R, Thomas S, Reddy JB, Pulimood A, Balasubramanian KA. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. Hepatology 2002; 35: 622-9.

  14. Sheth P, Basuroy S, Li C, Naren AP, Rao RK. Role of phosphatidylinositol 3-kinase in oxidative stress-induced disruption of tight junctions. J Biol Chem 2003; 278: 49239-45.

  15. Assimakopoulos SF, Gogos C, Labropoulou-Karatza C. Could antioxidants be the “magic pill” for cirrhosis-related complications? A pathophysiological appraisal. Med Hypotheses 2011; 77: 419-23.

  16. Banan A, Choudhary S, Zhang Y, Fields JZ, Keshavarzian A. Ethanol-induced barrier dysfunction and its prevention by growth factors in human intestinal monolayers: evidence for oxidative and cytoskeletal mechanisms. J Pharmacol Exp-Ther 1999; 291: 1075-85.

  17. Forsythe RM, Xu DZ, Lu Q, Deitch EA. Lipopolysaccharideinduced enterocyte-derived nitric oxide induces intestinal monolayer permeability in an autocrine fashion. Shock 2002;17: 180-4.

  18. Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteith P, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol- Gastrointest Liver Physiol 2012; 303: G675-85.

  19. Saitoh O, Sugi K, Lojima K, Matsumoto H, Nakagawa K, Kayazawa M, Tanaka S, et al. Increased prevalence of intestinal inflammation in patients with liver cirrhosis. World J Gastroenterol 1999; 5: 391-6.

  20. Iwao T, Toyonaga A, Ikegami M, Oho K, Sumino M, Harada H, Sakaki M, et al. Reduced gastric mucosal blood flow in patients with portal-hypertensive gastropathy. Hepatology 1993; 18: 36-40.

  21. Xu WH, Wu XJ, Li JS. Influence of portal pressure change on intestinal permeability in patients with portal hypertension. Hepatobiliary Pancreat Dis Int 2002; 1: 510-4.

  22. Ramachandran A, Balasubramanian KA. Intestinal dysfunction in liver cirrhosis: Its role in spontaneous bacterial peritonitis. J Gastroenterol Hepatol 2001; 16: 607-12.

  23. Zuwala-Jagiello J, Pazgan-Simon M, Simon K, Warwas M. Elevated advanced oxidation protein products levels in patients with liver cirrhosis. Acta Biochim Pol 2009; 56: 679-85.

  24. Chiva M, Soriano G, Rochat I, Peralta C, Rochat F, Llovet T, Mirelis B, et al. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 2002; 37: 456-62.

  25. Chiva M, Guarner C, Peralta C, Llovet T, Gomez G, SorianoG, Balanzo J. Intestinal mucosal oxidative damage and bacterial translocation in cirrhotic rats. Eur J Gastroenterol Hepatol 2003; 15: 145-50.

  26. Natarajan SK, Ramamoorthy P, Thomas S, Basivireddy J, Kang G, Ramachandran A, Pulimood AB, et al. Intestinal mucosal alterations in rats with carbon tetrachloride-induced cirrhosis: changes in glycosylation and luminal bacteria. Hepatology 2006; 43: 837-46.

  27. Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, Karatza E, Zisimopoulos D, Maroulis I, Kontogeorgou E, et al. Intestinal mucosal proliferation, apoptosis and oxidative stress in patients with liver cirrhosis. Ann Hepatol 2013; 12: 301-7.

  28. Pijls KE, Koek GH, Elamin EE, de Vries H, Masclee AA, Jonkers DM. Large intestine permeability is increased in patients with compensated liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 2014; 306: G147-53.

  29. Julicher RH, Sterrenberg L, Haenen GR, Bast A, Noordhoek J. The effect of chronic adriamycin treatment on heart kidney and liver tissue of male and female rat. Arch Toxicol 1988; 61: 275-81.

  30. van der Sluijs Veer G, van den Hoven B, Russel MG, van den Bergh FA. Time-resolved fluorimetric immunoassay of calprotectin: technical and clinical aspects in diagnosis of inflammatory bowel diseases. Clin Chem Lab Med 2006; 44: 292-8.

  31. de Haan JJ, Lubbers T, Hadfoune M, Luyer MD, Dejong CH, Buurman WA, Greve JW. Postshock intervention with highlipid enteral nutrition reduces inflammation and tissue damage. Ann Surg 2008; 248: 842-8.

  32. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidantand radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981; 78: 6858-62.

  33. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine: New York: Oxford University Press Inc.; 1999.

  34. Banan A, Fields JZ, Decker H, Zhang Y, Keshavarzian A. Nitric oxide and its metabolites mediate ethanol-induced microtubule disruption and intestinal barrier dysfunction. J Pharmacol Exp Ther 2000; 294: 997-1008.

  35. Sen SK, Packer L, Hanninen O. Handbook of Oxidants and Antioxidants in Exercise: Elsevir Science B.V.; 2000.

  36. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 2011; 412: 1297-305.




2020     |     www.medigraphic.com